Digital Health
搜索文档
Digital Initiative Strengthens Access to Mental Health Support: Region of Southern Denmark and Trifork Behind New Platform
Globenewswire· 2025-10-31 22:13
Press release (Danish version attached) Digital Initiative Strengthens Access to Mental Health Support: Region of Southern Denmark and Trifork Behind New Platform Aarhus, October 31, 2025 – The Region of Southern Denmark has signed a contract with Trifork for the development, implementation, and maintenance of the national Shared Public Treatment Platform (Fællesoffentlig Behandlingsplatform, FOB). The platform will make it easier to offer digital treatment and support programs to all Danish citizens. With ...
Butterfly Network Reports Third Quarter 2025 Financial Results
Businesswire· 2025-10-31 18:30
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly†or the "Company†), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, "We view this quarter as a period of foundational prog ...
HEALWELL's Orion Health Signs Memorandum of Understanding with Lean Business Services to Advance AI-Powered Healthcare in Saudi Arabia & Across the Middle East
Newsfile· 2025-10-30 15:15
HEALWELL's Orion Health Signs Memorandum of Understanding with Lean Business Services to Advance AI-Powered Healthcare in Saudi Arabia & Across the Middle EastOctober 30, 2025 3:15 AM EDT | Source: HEALWELL AIHEALWELL AI and its subsidiary Orion Health have signed a Memorandum of Understanding (MoU) with Lean Business Services, to jointly explore the development and commercialization of digital health and AI-driven solutions across the Middle East and Orion's global markets.The MoU leverages c ...
Thermo Fisher to buy clinical services provider Clario
Reuters· 2025-10-29 18:11
Thermo Fisher said on Wednesday it would buy privately held data management company Clario for about $8.9 billion in cash and future payments, strengthening the life science firm's presence in digital health and clinical trial research. ...
Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026
Globenewswire· 2025-10-28 20:30
Achieved key operational milestones establishing manufacturing capabilities to supply more than 2x the products required to achieve 2026 revenue targets BERKELEY, Calif, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces completion of key manufacturing initiatives to support 2026 Lumee™ tissue oxygen ...
Medical Care Technologies Inc. (OTC PINK:MDCE) Approved as Official Apple Developer
Accessnewswire· 2025-10-24 21:30
Company advances digital technology initiatives with approval to publish applications on Apple's App Store MESA, ARIZONA / ACCESS Newswire / October 24, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a technology-driven company specializing in innovative digital health and AI applications, today announced that it has been formally approved as an Apple Developer. This approval enables the company to create, test, and distribute mobile applications for iOS users worldwide. ...
[Latest] Global Biofeedback Instrument Market Size/Share Worth USD 340 Million by 2034 at a 6.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Globenewswire· 2025-10-15 20:30
市场概况与规模 - 全球生物反馈仪器市场规模在2024年约为1.94亿美元,预计到2025年将达到2.02亿美元,并预计在2034年增长至约3.4亿美元,预测期内(2025-2034年)的复合年增长率约为6.2% [3][12] - 生物反馈设备细分市场在2024年预计达到12.5亿美元的价值,并预计在2026年至2033年间以8.2%的高速率增长 [6][7] - 行业是数字健康和健康生态系统中一个快速增长且充满活力的部分,其发展得益于人们对身心关系日益增长的兴趣、对非侵入性治疗系统的需求以及生理监测技术的进步 [3] 产品与应用细分 - 产品类型主要包括肌电图生物反馈设备、脑电图生物反馈设备、热生物反馈设备、心率变异性设备等 [1][35][36] - 主要应用领域包括压力管理、疼痛管理、肌肉康复、注意力缺陷多动障碍治疗等,在临床医疗机构、健康以及体育、教育和企业环境中的表现优化方面均有应用 [1][4][36] - 最终用户涵盖医院、诊所、家庭医疗、研究机构等 [1][36] 关键增长驱动因素 - 技术创新的持续推动,包括传感器技术、数据处理和用户界面设计的改进,例如MindMaster Bio Series可同时记录数百项生理指标,Mitsar EEG系统具有21个通道 [10] - 临床应用的扩展和与医疗保健体系的整合,生物反馈被广泛应用于多种临床领域和治疗干预,医疗专业人员日益认识到其在整体治疗计划中的重要性 [10] - 消费市场的增长,由健康趋势、压力管理需求和表现优化应用驱动,可穿戴设备、移动应用等使技术更易为普通消费者所及 [10] - 在预防性医疗保健、压力管理和个性化健康解决方案方面不断增长的消费者需求推动了市场增长 [4] 区域市场分析 - 北美市场在全球处于领先地位,拥有发达的医疗基础设施、广泛的研究实践以及对医疗设备发展的积极态度,现有的针对循证用途的报销政策支持了市场发展 [5][19][23] - 欧洲市场以良好的监管、发达的医疗系统以及对主流医疗中补充疗法日益增长的兴趣为特点,该地区强调循证医学 [5][21] - 亚太地区拥有最强的增长潜力,原因在于新兴的医疗基础设施、不断增加的医疗投资以及城市人口对心理健康问题的认识提高,该地区显示出对移动医疗的技术接纳,有利于消费导向设备的发展 [5][22][25] - 拉丁美洲、中东和非洲地区存在温和的增长机会,但面临财务限制、专家稀缺和不同监管环境等挑战 [26][29] 主要市场参与者 - 行业内的知名公司包括Thought Technology Ltd、Mind Media B.V.、BrainMaster Technologies Inc.、Bio-Medical Instruments Inc.、Mindfield Biosystems Ltd等 [30][33] - 成熟的制造商生态系统(包括如Bio-Medical Instruments, Mindfield和Thought Technology等公司)带来了成熟的供应链和技术专长 [16]
Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025
Globenewswire· 2025-10-10 04:05
财报发布安排 - 公司计划于2025年10月30日纽约证券交易所收盘后发布2026财年第一季度财务和运营业绩 [1] - 业绩发布后管理层将举办网络直播讨论结果并可能讨论其他前瞻性和重要信息 [1] - 网络直播仅可通过指定链接访问公司未使用外部电话线路接入电话会议 [1] 网络直播详情 - 网络直播时间为2025年10月30日下午1:30 PDT / 下午4:30 EDT [3] - 国际时间对应为伦敦2025年10月30日晚8:30 GMT悉尼2025年10月31日早7:30 AEDT [3] - 电话重播将于网络直播后约三小时提供可从2025年10月30日获取至2025年11月13日 [2][4] 公司业务概览 - 公司致力于开发改变生活的健康技术在140个国家为数百万人提供支持 [2] - 业务核心为AI驱动的数字健康解决方案、云连接设备和智能软件旨在使家庭医疗更个性化、可及和有效 [2] - 公司愿景是让每个人都能通过改善睡眠和呼吸在自家获得护理从而发挥全部潜能 [2]
Eli Lilly (NYSE:LLY) Receives Overweight Rating from Cantor Fitzgerald with Increased Price Target
Financial Modeling Prep· 2025-10-10 01:05
投资评级与价格目标 - Cantor Fitzgerald重申对公司的“增持”评级,并将目标股价从825美元上调至925美元,显示对公司未来表现的信心 [1][5][6] - 公司股票交易价格为845.72美元,当日小幅上涨2.09美元,涨幅约0.25% [1][4] 战略合作与业务发展 - 公司与远程医疗公司HealthTap建立战略合作伙伴关系,以增强其数字医疗平台LillyDirect [2][5][6] - 此次合作专注于提供虚拟糖尿病管理服务,符合公司改善患者护理的承诺 [2] 核心团队增强 - 公司聘请美国食品药品监督管理局前高级疫苗监管官员Peter Marks加入团队 [3][5][6] - Peter Marks在疫苗监管方面的专业知识预计将成为公司的宝贵资产,支持其推进药物创新 [3] 市场表现与财务数据 - 公司当前股价在845美元至856美元之间波动,52周最高价为937美元,最低价为623.78美元 [4] - 公司市值约为7606亿美元,凸显其在制药行业的显著地位 [4] - 纽约证券交易所当日成交量为1,710,585股,表明投资者兴趣活跃 [5]
Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel
Globenewswire· 2025-10-06 13:00
Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function.This tool will be launched as part of Roche’s new chronic kidney disease (CKD) algorithm panel to support care across the stages of the disease which affects 700 million people globally.Clinicians can use the CKD panel (Kidney Klinrisk Algorithm and Kidney KFRE Algorithm) to evaluate a patient’s risk of kidney function decline, including in ...